172 related articles for article (PubMed ID: 34853322)
1. Targeting SYK of monocyte-derived macrophages regulates liver fibrosis via crosstalking with Erk/Hif1α and remodeling liver inflammatory environment.
Chen X; Wang Z; Han S; Wang Z; Zhang Y; Li X; Xia N; Yu W; Jia C; Ni Y; Pu L
Cell Death Dis; 2021 Dec; 12(12):1123. PubMed ID: 34853322
[TBL] [Abstract][Full Text] [Related]
2. Targeting SYK signaling in myeloid cells protects against liver fibrosis and hepatocarcinogenesis.
Torres-Hernandez A; Wang W; Nikiforov Y; Tejada K; Torres L; Kalabin A; Wu Y; Haq MIU; Khan MY; Zhao Z; Su W; Camargo J; Hundeyin M; Diskin B; Adam S; Rossi JAK; Kurz E; Aykut B; Shadaloey SAA; Leinwand J; Miller G
Oncogene; 2019 Jun; 38(23):4512-4526. PubMed ID: 30742098
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis.
Qu C; Zheng D; Li S; Liu Y; Lidofsky A; Holmes JA; Chen J; He L; Wei L; Liao Y; Yuan H; Jin Q; Lin Z; Hu Q; Jiang Y; Tu M; Chen X; Li W; Lin W; Fuchs BC; Chung RT; Hong J
Hepatology; 2018 Sep; 68(3):1125-1139. PubMed ID: 29537660
[TBL] [Abstract][Full Text] [Related]
5. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor activation in myeloid cells contributes to the development of liver fibrosis in cholestatic mice.
Copple BL; Kaska S; Wentling C
J Pharmacol Exp Ther; 2012 May; 341(2):307-16. PubMed ID: 22271822
[TBL] [Abstract][Full Text] [Related]
7. LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis.
Klepfish M; Gross T; Vugman M; Afratis NA; Havusha-Laufer S; Brazowski E; Solomonov I; Varol C; Sagi I
Front Immunol; 2020; 11():480. PubMed ID: 32296422
[TBL] [Abstract][Full Text] [Related]
8. TGF-β Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1α-Induced Epithelial Mesenchymal Transition.
Kim MJ; Park SA; Kim CH; Park SY; Kim JS; Kim DK; Nam JS; Sheen YY
Cell Physiol Biochem; 2016; 38(2):571-88. PubMed ID: 26845171
[TBL] [Abstract][Full Text] [Related]
9. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice.
Moon JO; Welch TP; Gonzalez FJ; Copple BL
Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G582-92. PubMed ID: 19136383
[TBL] [Abstract][Full Text] [Related]
10. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation, and Hepatic Fibrosis in the Abcb4
Krishnan A; Katsumi T; Guicciardi ME; Azad AI; Ozturk NB; Trussoni CE; Gores GJ
Am J Pathol; 2020 Jun; 190(6):1284-1297. PubMed ID: 32240619
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of spleen tyrosine kinase (syk) suppresses renal fibrosis through anti-inflammatory effects and down regulation of the MAPK-p38 pathway.
Chen KH; Hsu HH; Yang HY; Tian YC; Ko YC; Yang CW; Hung CC
Int J Biochem Cell Biol; 2016 May; 74():135-44. PubMed ID: 26948651
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis.
Kurniawan DW; Jajoriya AK; Dhawan G; Mishra D; Argemi J; Bataller R; Storm G; Mishra DP; Prakash J; Bansal R
J Control Release; 2018 Oct; 288():227-238. PubMed ID: 30219279
[TBL] [Abstract][Full Text] [Related]
13. PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
She S; Wu X; Zheng D; Pei X; Ma J; Sun Y; Zhou J; Nong L; Guo C; Lv P; Song Q; Zheng C; Liang W; Huang S; Li Q; Liu Z; Song Z; Li Y; Zhang Y; Kong W; You H; Xi J; Wang Y
J Hepatol; 2020 Mar; 72(3):506-518. PubMed ID: 31813573
[TBL] [Abstract][Full Text] [Related]
14. Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury.
Mossanen JC; Krenkel O; Ergen C; Govaere O; Liepelt A; Puengel T; Heymann F; Kalthoff S; Lefebvre E; Eulberg D; Luedde T; Marx G; Strassburg CP; Roskams T; Trautwein C; Tacke F
Hepatology; 2016 Nov; 64(5):1667-1682. PubMed ID: 27302828
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase B (AKT) regulates SYK activity and shuttling through 14-3-3 and importin 7.
Mohammad DK; Nore BF; Gustafsson MO; Mohamed AJ; Smith CIE
Int J Biochem Cell Biol; 2016 Sep; 78():63-74. PubMed ID: 27381982
[TBL] [Abstract][Full Text] [Related]
16. Isoliquiritigenin Attenuates UUO-Induced Renal Inflammation and Fibrosis by Inhibiting Mincle/Syk/NF-Kappa B Signaling Pathway.
Liao Y; Tan RZ; Li JC; Liu TT; Zhong X; Yan Y; Yang JK; Lin X; Fan JM; Wang L
Drug Des Devel Ther; 2020; 14():1455-1468. PubMed ID: 32341639
[TBL] [Abstract][Full Text] [Related]
17. microRNA-322/424 promotes liver fibrosis by regulating angiogenesis through targeting CUL2/HIF-1α pathway.
Wang Q; Zhang F; Lei Y; Liu P; Liu C; Tao Y
Life Sci; 2021 Feb; 266():118819. PubMed ID: 33333053
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice.
Baeck C; Wei X; Bartneck M; Fech V; Heymann F; Gassler N; Hittatiya K; Eulberg D; Luedde T; Trautwein C; Tacke F
Hepatology; 2014 Mar; 59(3):1060-72. PubMed ID: 24481979
[TBL] [Abstract][Full Text] [Related]
19. Inducible T-Cell Costimulator Mediates Lymphocyte/Macrophage Interactions During Liver Repair.
Ramavath NN; Gadipudi LL; Provera A; Gigliotti LC; Boggio E; Bozzola C; Albano E; Dianzani U; Sutti S
Front Immunol; 2021; 12():786680. PubMed ID: 34925367
[TBL] [Abstract][Full Text] [Related]
20. SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis.
Luci C; Vieira E; Bourinet M; Rousseau D; Bonnafous S; Patouraux S; Lefevre L; Larbret F; Prod'homme V; Iannelli A; Tran A; Anty R; Bailly-Maitre B; Deckert M; Gual P
Cell Mol Gastroenterol Hepatol; 2022; 13(1):173-191. PubMed ID: 34411785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
